Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
Health Canada-authorized trial to evaluate a single supervised dose of natural psilocybin, with dosing expected to be completed by the end of 2027 Up to 200 participants at sites across Canada, among the largest studies of naturally derived psilocybin to date VANCOUVER, British Columbia, Sept. 10, 2026 (GLOBE NEWSWIRE) — Optimi Health Corp. (Nasdaq: OPTH) […]
Financial Post
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from Financial Post.
In this story
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
Financial Post (financialpost.com), a Tier B publisher, filed this report on . CurrentWire published this page 12 minutes later, on .
Signal breakdown
CurrentWire ranked this story 61.9 of 100 in the snapshot this page was rendered from.
- Freshness
- 34.4 of 35
- Source authority
- 7 of 20
- Coverage breadth
- 4 of 20
- Geographic relevance
- 10 of 10
- Story prominence
- 6.5 of 10
- Velocity
- 0 of 5
Strongest signal: geographic relevance, 10 of 10. How each signal is calculated.
Filed under Health · Canada · Press release. Topics extracted from this report, with other live CurrentWire stories mentioning each: Health Canada (none), Canada (25), Vancouver (3), British Columbia (2), Initiate Phase (none), Clinical Trial Evaluating Psilocybin-Assisted Therapy (none), Major Depressive Disorder (none).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.